Aurobindo Pharma Q3 FY23 net profit down 18.7% at Rs 491 Crores
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
Revenue from operations during the quarter was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal.
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
A centralised kitchen which provides 5,000 breakfast meals per day is to be started at Perumallapuram, Kakinada, Andhra Pradesh
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
With the implementation of this project, a total of 1,030 acres of cultivable land can be irrigated per crop cycle
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
The brand is now available pan-India through their distribution partner
Subscribe To Our Newsletter & Stay Updated